MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer ...

BioNTech SE shared its Q3 earnings, business updates, and guidance for 2025 earlier today. Its share price is down 1% in trading so far. BNTX maintains a strong cash position, driven by ongoing ...

BioNTech SE's $11.1bn BMS deal for BNT-327 highlights promise in PD-L1/VEGF oncology, but clinical validation is still needed. Despite strong COVID vaccine cash flow, BioNTech's share price stagnates ...

(Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer ...

BioNTech SE (NASDAQ:BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ:CVAC) in an all-stock transaction. According to the agreement, shareholders can exchange CureVac shares for around $5.46 in ...

BioNTech and Bristol Myers Squibb have announced a partnership for the global co-development and co-commercialization of BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, which aims to improve ...

As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey. With plans to have at least 10 ...

BioNTech is spending more of its COVID cash, betting over $1 billion on a licensing deal for a phase 2 bispecific antibody, just days after closing the acquisition of a lipid nanoparticle startup.

BioNTech has struck a deal to explore oral delivery of mRNA vaccines. Working with Matinas BioPharma, the German mRNA specialist will study the potential for a lipid nanocrystal (LNC) platform to ...

A combination mRNA cancer vaccine from BioNTech and Regeneron may be one step closer to actualization based on initial Phase 2 results unveiled Tuesday. The mRNA-based vaccine, BNT111, in combination ...

Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech at $1.25 billion. The announcement makes no specific mention of onboarding ...